Darlene Dobkowski, MA


Lenvatinib May Provide Survival Benefit With Manageable Toxicities in Recurrent HCC After Liver Transplantation

January 21st 2022

Lenvatinib was effective in treating patients with recurrent hepatocellular carcinoma after liver transplantation and demonstrated manageable toxicities.

Acalabrutinib Provides Long-Term Survival Benefits Vs. Standard of Care in Relapsed/Refractory Chronic Lymphocytic Leukemia

December 12th 2021

Treatment with acalabrutinib for relapsed/refractory chronic lymphocytic leukemia was effective out to 3 years and demonstrated a progression-free survival benefit over standard of care, according to 3-year follow-up of the ASCEND study.

Real-World Efficacy of Tisagenlecleucel in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Similar to Clinical Trial Data With Improved Safety Outcomes

December 12th 2021

Real-world data of children and young adults with relapsed/refractory B-cell acute lymphoblastic leukemia treated with tisagenlecleucel demonstrated similar efficacy outcomes and a more favorable safety profile compared with the ELIANA trial.

AEs Related to Olaparib Treatment May Be Easily Mitigated in High-Risk Early Breast Cancer

December 10th 2021

Certain adverse effects associated with olaparib were minimal and resolved with appropriate management in patients with germline BRCA1/2 mutations in patients with high-risk, HER2-negative, early-stage breast cancer.

Datopotamab Deruxtecan May Lead to Antitumor Activity in Advanced NSCLC With Genomic Alterations

September 19th 2021

The antibody drug conjugate datopotamab deruxtecan demonstrated safe antitumor activity in patients with advanced/metastatic non-small cell lung cancer with actionable genomic alterations.

VHL-Mutated and VHL Wild-Type Clear Cell RCC May Present Similar Clinical Characteristics

September 17th 2021

Similarities in clinical characteristics in these patients despite differences in other genomic alterations may impact potential clinical trial treatment selection.

MRD Could Play Role in Predicting Post-ASCT Outcomes in Myeloma

September 9th 2021

For patients with myeloma have undergone an autologous stem cell transplant and are currently on maintenance therapy with lenalidomide, minimal residual disease may be a powerful predictor of outcomes.

Daratumumab Plus Combination Therapy May Be New Standard of Care for Newly Diagnosed Multiple Myeloma

September 9th 2021

Older patients with newly diagnosed multiple myeloma who are ineligible for chemotherapy or transplant may derive a greater benefit when treated with daratumumab plus lenalidomide and dexamethasone compared with lenalidomide and dexamethasone.

Frontline Ibrutinib/Venetoclax Yields Superior Outcomes Vs Chlorambucil/Obinutuzumab in CLL

June 12th 2021

Fixed-duration ibrutinib and venetoclax as a first-line treatment yielded superior progression-free survival compared with chlorambucil plus obinutuzumab in patients with chronic lymphocytic leukemia.

Cilta-Cel Demonstrates Durable Responses at 18 Months in Relapsed/Refractory Multiple Myeloma

June 8th 2021

Ciltacabtagene autoleucel, an investigational BCMA-directed CAR-T therapy, sustained efficacy and durable responses in heavily pretreated patients with relapsed/refractory multiple myeloma.

Triplet Combination Safe, Effective for Relapsed/Refractory DLBCL

June 5th 2021

Patients with relapsed/refractory diffuse large B-cell lymphoma treated with a novel combination of polatuzumab vetodin, rituximab and lenalidomide contributed to an improved overall response and complete response, with 82% remaining in remission at the study’s cutoff date.

PFS Improved With Niraparib Maintenance in BRCA+ Ovarian Cancer

June 4th 2021

Maintenance therapy with niraparib significantly improved progression-free survival in patients with BRCA-mutated ovarian cancer, according to results from three phase 3 trials.

States With Lower Medicaid Eligibility Limits May Have Worse Survival Rates Among Patients with Cancer

May 19th 2021

Patients with cancer who live in states with lower Medicaid income eligibility limits had worse long-term survival outcomes compared with those with higher eligibility limits.

Higher Lenvatinib Dose May Improve QoL in RCC

February 11th 2021

February 11, 2021 - A higher starting dose of lenvatinib — 18 mg per day — improved health-related quality of life and led to longer time to deterioration compared with a lower starting dose of lenvatinib — 14 mg per day — in patients with renal cell carcinoma.

Clinicians May Need to Further Educate Their Patients About Treatment Options During Decision-Making Process

January 28th 2021

January 28, 2021 - Although survivors and patients with lung cancer felt that they were involved in the treatment decision-making process, nearly half of them reported that they knew what their treatment options were before making a decision.

Invasive Gastrointestinal Stromal Tumors More Common in Men, Initiating in the Small Intestine and Stomach

January 15th 2021

January 15, 2021 - Findings from an analysis determined that stage 4 gastrointestinal stromal tumors were rare and led to hepatic metastases, although overall survival was up to 51% at 5 years.

Combination Therapy with Tesetaxel and Capecitabine Improves PFS in HER2-, HR+ Metastatic Breast Cancer

December 11th 2020

December 11, 2020 - Patients with human epidermal growth factor receptor 2-negative, hormone receptor-positive metastatic breast cancer who were treated with tesetaxel and a reduced dose of capecitabine experienced improvements in progression-free survival compared with those treated with the FDA-approved dose of capecitabine alone.

Greater Adherence to a Diet for Diabetes Reduction May Improve Survival for Breast Cancer

December 10th 2020

December 10, 2020 - Women with stage 1 to 3 breast cancer who adhered to a diabetes risk reduction diet had improved survival versus those who did not follow this specific diet.

Survival Benefit of Venetoclax and Rituximab in Relapsed/Refractory CLL Persists Out to Five Years

December 5th 2020

December 5, 2020 - Patients with relapsed or refractory chronic lymphocytic leukemia treated with venetoclax and rituximab had a sustained progression-free survival and overall survival benefit at five years compared with those treated with bendamustine and rituximab.